All subjects
| Compound | Company | Phase | Target | Route | Links |
|---|---|---|---|---|---|
| Baricitinib Olumiant Severe alopecia areata only | Eli Lilly | ApprovedFDA approved · EMA approved | — | oral | — |
| Deuruxolitinib CTP-543 / Leqselvi JAK1/JAK2 inhibitor Severe alopecia areata only | Sun Pharma | ApprovedFDA approved | — | oral | — |
| Ritlecitinib Litfulo Severe alopecia areata only | Pfizer | ApprovedFDA approved · EMA approved | — | oral | — |
| Upadacitinib Rinvoq Severe alopecia areata only | AbbVie | ApprovedEMA approved · FDA pending | — | oral | — |
| Clascoterone Breezula | Cosmo Pharmaceuticals | Phase 3 | early 2027 US NDA filing sponsor, Apr 2026 | topical | NCT05910450 |
| Extended-release oral minoxidil VDPHL01 | Veradermics | Phase 3 | H1 2027 female phase 2/3 topline data sponsor, Oct 2026 | oralextended-release tablet | NCT06972264 |
| Pyrilutamide KX-826 | Kintor | Phase 3 | 2027 China approval (NDA filing H2 2026) sponsor, Aug 2026 | topical | NCT06126965 |
| Sublingual minoxidil SAM-002 | Samson Clinical | Phase 3 | 2026 EU · 2029 US regulatory submission sponsor, May 2026 | sublingualsublingual tablet | NCT06924632 |
| Topical dutasteride 0.05% | Shilpa Medicare | Phase 3 | FY27 (to Mar 2027) phase 3 completion sponsor, Feb 2026 | topical | CTRI/2026/05/110983 results |
| DLQ01 Prostaglandin F2α analog | Dermaliq | Phase 2 | — | topical | NCT05636904 |
| GT20029 Androgen-receptor PROTAC | Kintor | Phase 2 | H2 2026 phase 2b/3 start (China) sponsor, Aug 2026 | topical | NCT06692465 |
| HMI-115 BAY-1158061 | Bayer / Hope Medicine | Phase 2 | — | injection | NCT06118866 |
| PP405 Suvomipic | Pelage Pharmaceuticals | Phase 2 | end 2026 phase 2 in women starts sponsor, Oct 2026 | topical | NCT07819435 |
| TDM-105795 Thyromimetic | Technoderma | Phase 2 | — | topical | NCT05802173 |
| ABS-201 Prolactin-receptor antibody | AbSci | Phase 1 | early 2027 full phase 1 data sponsor, Aug 2026 | injection | NCT07317544 |
| AMP-303 | Amplifica | Phase 1 | — | injection | results developer |
| ET-02 hair follicle stem cell restoration (mechanism undisclosed) | Eirion Therapeutics | Phase 1 | 2027 phase 2 start sponsor, Sep 2026 | topical | results developer |
| JW0061 GFRA1 agonist | JW Pharmaceutical | Phase 1 | — | — | NCT07514780 |
| OLX104C RNA interference | OliX Pharmaceuticals | Phase 1 | end 2026 phase 2a first patient dosed sponsor, Aug 2026 | injection | NCT07327359 developer |
| 2-Deoxy-D-ribose Pro-angiogenic sugar | University of Sheffield | Preclinical | — | topical | NCT07502976 |
| AMP-203 / AMP-506 Osteopontin | Amplifica | Preclinical | — | — | developer |
| AMP-601 SCUBE3 | Amplifica | Preclinical | — | — | developer |
| Bee venom Melittin · IGF-1 / VEGF | — | Preclinical | — | — | — |
| Exosomes Extracellular vesicle signalling | — | Preclinical | — | — | — |
| miR-218-5p MicroRNA therapy | — | Preclinical | — | — | — |
| Oleic acid serum | National Taiwan University | Preclinical | — | topical | — |
| OND-1 Cyclosporine A derivative | Orient Bio | Preclinical | — | topical | developer |
| RLS-1496 GPX4 modulator | Rubedo Life Sciences | Preclinical | H1 2027 first data from a trial starting Oct 2026 sponsor, Sep 2026 | topical | — |
| YCH001 iPSC follicle regeneration | Yunce Medical | Preclinical | — | — | developer |
| Follicopeptide FOL-005 drug programme ended; sold as a cosmetic ingredient since 2025 | Coegin Pharma | Discontinued | — | topical | NCT02793557 developer |
Registry links go to ClinicalTrials.gov or the WHO registry record. Target = the sponsor's own stated date for its next milestone, linked to where it said so, with the month it said it. Sponsors move these dates; we show the latest we have read.
This view is modelled on the excellent Hair Loss Pipeline Tracker.